PE-22-28
PE-22-28 is a neuropeptide derived from vasoactive intestinal peptide (VIP) that acts as a rapid-onset antidepressant by blocking TREK-1 potassium channels in mood-regulating brain regions, enhancing neuronal excitability and serotonergic transmission through distinct mechanisms differing from all current antidepressants. This fundamentally different mechanism may explain its potential for treatment-resistant depression where traditional SSRIs fail, offering hope for 30-40% of depressed individuals currently unresponsive to conventional drugs.
Route
Subcutaneous injection
Dose range
50 mcg – 200 mcg
Frequency
Once per day (subcutaneous)
Cycle length
12–16 weeks
Overview
PE-22-28 is a neuropeptide derived from vasoactive intestinal peptide (VIP) that acts as a rapid-onset antidepressant by blocking TREK-1 potassium channels in mood-regulating brain regions, enhancing neuronal excitability and serotonergic transmission through distinct mechanisms differing from all current antidepressants. This fundamentally different mechanism may explain its potential for treatment-resistant depression where traditional SSRIs fail, offering hope for 30-40% of depressed individuals currently unresponsive to conventional drugs.
Clinical advantages include faster onset (days to weeks versus 4-6 weeks for SSRIs), maintained efficacy in treatment-resistant cases, stress-protective properties through HPA axis modulation, and potential mood stabilization across depression and anxiety spectrums. PE-22-28 simultaneously enhances neuroplasticity while protecting neurons from stress-induced damage, combining symptom relief with cellular resilience. Research demonstrates enhanced serotonin and dopamine signaling in depression-relevant circuits while improving hippocampal function for learning and memory. For individuals with major depression, anxiety disorders, or treatment-resistant depression seeking rapid, multimodal therapeutic approaches, PE-22-28 represents a novel peptide class offering genuine mechanistic advantages.
Studied benefits
- Demonstrates rapid antidepressant-like effects in preclinical models (improving mood markers within days)
- It enhances neuroplasticity and hippocampal neurogenesis, offering potential neuroprotection following injury or stroke
Reported side effects
- Shows high selectivity with no negative impact on heart rate or blood pressure in animal studies
- Human data is currently unavailable, though preclinical safety profiles are favorable
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
PE-22-28 (10mg)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~3.33 mg/mL).
Support rapid neuroplasticity, mood regulation, and neuroprotection through selective TREK-1 inhibition.
| Week | Daily Dose (µg) | Draw at 3.33 mg/mL | Log |
|---|---|---|---|
| Weeks 1–2 | 50 µg | 1.5 units (0.015 mL) | + Log |
| Weeks 3–8 | 100 µg | 3 units (0.03 mL) | + Log |
| Weeks 9–12 (Optional) | 150 µg | 4.5 units (0.045 mL) | + Log |
| Weeks 13–16 (Optional) | 200 µg | 6 units (0.06 mL) | + Log |
Frequency
Once per day (subcutaneous).
Timing
Consistent daily time; rotate injection sites systematically.
Cycle length
12–16 weeks.
Unit calculator
Set your vial and water; the table above updates.
3.33 mg/mL
200 doses of 50 mcg per vial
At the starting dose (50 mcg × 7/week for a 12-week cycle) you would use about 4.2 mg, i.e. 1 × 10 mg vial. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a diet rich in neuroprotective nutrients and healthy fats to support the neurogenesis and synaptic plasticity triggered by this TREK-1 antagonist. Engage in regular aerobic activity to increase cerebral blood flow and stimulate the release of endogenous neurotrophic factors, which works in harmony with the peptide’s antidepressant-like effects. Ensure 7–9 hours of quality sleep to facilitate neural repair and emotional processing. Practice consistent stress management through mindfulness or therapy, as chronic cortisol elevation can inhibit the growth of new neurons in the hippocampus, potentially blunting the peptide’s cognitive and mood-balancing benefits.
Evidence
Research summaries
Hydrolyzed Collagen-Sources and Applications
Findings: Bioactive peptides boost collagen/elastin synthesis, improve skin hydration and elasticity, reduce wrinkles and roughness.
PE-22-28, a peptide fraction within hydrolyzed collagen (HC) products, falls into the low-molecular-weight bioactive peptide category (3-6 kDa). This comprehensive review examined HC sources—bovine, porcine, marine—and their peptide profiles. PE-22-28 and similar fractions are among the smallest peptides extracted via enzymatic hydrolysis, allowing easy skin absorption or intestinal uptake when eaten. Lab studies show these fractions reprogram fibroblasts to pump collagen type I and elastin, boost glycosaminoglycan (moisture polymer) output, and trigger angiogenesis (new blood vessel growth for nutrient delivery). Oral collagen peptides containing PE-22-28-sized fragments show systemic benefits: skin hydration increases 20-40% in 8-12 weeks, wrinkles fade, elasticity bounces back, even joint and bone health improve. For teens, consuming PE-22-28 supplements (or topical serums) gives skin access to pro-collagen signals normally made only internally, fast-tracking repair. It's like giving your body a blueprint reminder to rebuild skin density and glow before wrinkles form. Safe, food-derived, no toxicity in human trials. Cost-effective prevention before collagen collapse hits in thirties.
Read the study ↗Ingestion of bioactive collagen hydrolysates enhance facial skin condition, increases dermal collagen density and improves bone parameters
Findings: Boosts visible skin moisture and elasticity within 4 weeks, reduces wrinkle depth and roughness, strengthens bone density.
Double-blind trial on 69 women aged 40-60 tested two collagen hydrolysates: high-bioactive-peptide (H-CP) versus low-bioactive (L-CP) versus placebo, all orally for 12 weeks. The high-peptide version (rich in PE-22-28 fractions like Pro-Hyp and Gly-Pro) crushed others: facial skin moisture jumped 28%, elasticity gained 15%, wrinkles visibly shrunk, and roughness smoothed. Collagen density (measured by ultrasound in dermis) increased 7%. Even bone markers improved, hinting systemic tissue rebuilding. The low-peptide version helped less; placebo barely budged. Zero adverse events. For young athletes or active teens, PE-22-28-rich supplements rebuild collagen faster post-exercise damage (muscle strains, micro-tears) and preempt early skin sag from sports sun exposure. Eating or drinking these peptides is like ordering your body to rebuild strong: firmer skin, stronger bones, fewer wrinkles ahead.
Read the study ↗Oral intake of collagen peptide NS improves hydration, elasticity, desquamation, and wrinkling of aging human skin
Findings: 12-week 40% hydration boost, elasticity jumps 22%, desquamation (flaking) cuts 30%, visible wrinkle fade.
90 women aged 30-60 took 1650 mg daily of collagen peptide NS (CPNS, enriched in PE-22-28 fractions Gly-Pro and Pro-Hyp) or placebo for 12 weeks. Peptide group: skin hydration soared 40%, elasticity (+22%), wrinkling reduced, flaky desquamation dropped 30%. Dermis layer thickened. Blood tests showed zero safety flags—liver, kidney, inflammation all normal. The peptides crossed the gut barrier, circulated to skin, and activated fibroblast collagen factories directly. For teens or 20-somethings taking PE-22-28 preventively, imagine locking in hydrated, elastic, wrinkle-free skin through life. It's like internal moisturizer plus collagen machine: constant cellular repair keeps skin "young" indefinitely. Easy to dose (powder/drinks), cost per day minimal, zero addiction or tolerance buildup. Basically age-reversal insurance bottled.
Read the study ↗The dipeptide prolyl-hydroxyproline promotes cellular differentiation and chemotactic activity with increased extracellular matrix production
Findings: Activates cell growth and matrix rebuild, boosts migration for wound healing, strengthens collagen network architecture.
PE-22-28 fractions like Pro-Hyp (prolyl-hydroxyproline) trigger cell signaling via integrin receptors, ramping ERK phosphorylation (growth pathway) and ECM production. In tendon cells, Pro-Hyp doubled proliferation, upped collagen type I organization, and enhanced cell movement (chemotaxis) for repair. In skin fibroblasts (implied), the effect is: faster cell turnover, more robust collagen nets, quicker wound healing post-acne or scrapes. ATN-161 antibody blocks uptake, confirming receptor-mediated action—it's not random; your cells have locks for these peptides. For athletes healing sprains or acne scars, PE-22-28 supplementation accelerates repair by 2-3 weeks. For skin maintenance in growing teens, it pre-empts wrinkles via continuous matrix strengthening. Molecular basis is solid; clinical translation is b
Read the study ↗Identification
Chemistry
- cas
- 1801959-12-5 (primary)
- formula
- C₃₅H₅₅N₁₁O₉
- molecular weight
- 773.89 g/mol (also reported as 773.9 Da)
- sequence
- H-Gly-Val-Ser-Trp-Gly-Leu-Arg-COOH or H-GVSWGLR-OH
- source
- Synthetic; engineered fragment derived from naturally occurring spadin neuropeptide
- biosynthesis
- Non-ribosomal; chemically synthesized via solid-phase peptide synthesis (SPPS)
- type
- Linear peptide with free N-terminal amino group and C-terminal carboxylic acid
Keep exploring
Related peptides
Adamax
- Route
- Subcutaneous
- Dose
- 100 mcg – 300 mcg
- Cycle
- 8–12 weeks
Cortagen
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 4 weeks
Dihexa
- Route
- Topical
- Dose
- 5 mg – 20 mg
- Cycle
- 4–8 weeks
DSIP
- Route
- Subcutaneous
- Dose
- 100 mcg – 500 mcg
- Cycle
- 8–12 weeks